Trial Profile
Open labeled, 16-weeks study for efficacy of Reslizumab uncontrolled chronic rhinosinusitis with nasal polyps
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Jan 2021
Price :
$35
*
At a glance
- Drugs Reslizumab (Primary) ; Mometasone
- Indications Nasal polyps; Rhinosinusitis
- Focus Therapeutic Use
- 21 Jan 2021 New trial record